A valid approach to treating frontal fibrosing alopecia (FFA), a scarring alopecia, does not yet exist. The aim of this study is to evaluate the efficacy of a topical application composed of minoxidil, hydrocortisone butyrate, 17a-estradiol, ciclosilicone pentamer, and alcohol in women affected by FFA. Forty women affected by FFA were treated with 2 ml of a topical lotion composed of 2% minoxidil base, 0.08% hydrocortisone butyrate, 0.05% 17a-estradiol, 16% ciclosilicone pentamer, 96°alcohol, applied once a day on the scalp. A score index, based on the comparison of the photos, taken at the beginning (TO) and after 36 months (T36), was used. The topical lotion led to an improvement in 20 patients, stabilization in 15 patients and worsening of the clinical condition in 5 women. This topical lotion induces a considerable improvement or stabilization of frontal fibrosing alopecia.
Frontal fibrosing alopecia (FFA) is classified as a scarring alopecia and was described for the first time by Kossard in 1994 in postmenopausal women (1). The disorder has also been described in younger women (2) and men (3, 4) . Clinical diagnosis shows that FFA is characterized by frontal hairline recession that usually occurs symmetrically and bilaterally leading to a band of alopecia between 0.5 ern and 8 em from the original hairline. In the last phase, it is possible to observe a total loss of hair from the frontoparietal area, resulting in the "clown" pattern. Infrequently, some patients may have fibrosing alopecia that starts from the occipital site or is involved secondarily in this area (4) .
In FFA, the skin ofthe scalp appears pale, smooth, and clear, with loss of follicular orifices, sometimes associated with inflammatory papules, follicular and perifollicular erythema and mild follicular hyperkeratosis (5) (6) (7) (8) (9) .
These manifestations characterize the initial stages of FFA and correlate with the inflammatory phase of the disease (2) . In literature, the thinning and partial loss of eyebrows, especially in the third lateral area, have been reported (10) .
FFA typically affects vellus-like hair because it is more susceptible to mild lymphocytic aggression. Histologically, it is possible to observe the selective involvement of intermediate and vellus-like follicles ofthe frontal margin and the eyebrows. Furthermore, in FFA inflammatory infiltrate is perinfundibular and peristhmus, associated with a prominent perifollicular fibrosis and a relevant presence of apoptotic cells.
The aim of this study is to show the efficacy of a lotion, composed of 2% minoxidil, 0.08% hydrocortisone butyrate, and 0.05% 17a-estradiol, applied on a sample of 40 patients affected by FFA. We based our study on the concept that these three molecules can act in combination and delay the development of the disease by blocking hair loss and fibrosis, leading to new hair growth. The choice of minoxidil was based on its well-known efficacy in shortening telogen, prolonging the anagen phase and for its antifibrotic activity (11). The support of hydrocortisone butyrate was used to block the inflammatory process (2, 12) . Finally, oestrogens are potent hair-growth modulators (13). Basing on this biological background, we decided to evaluate the efficacy and tolerability of this lotion in treating FFA.
MATERIALS AND METHODS

Experimental group
This study was undertaken after approval by the Ethics Committee of "Sapienza" University of Rome (Prot. 970/13, Rif. 2948/24.10.2013).
In our observational cohort study we enrolled 40 female patients affected by FFA. The follow-up was 36 months. Women aged between 48 and 60 years, affected by FFA, with no comorbidities were eligible for this study. Clinical diagnosis was confirmed by videodermatoscopic and histological examination. Punch biopsies (5 mm) were performed in the frontal area and were analyzed histologically after staining with hematoxylin and eosin. The main exclusion criteria included significant abnormalities on screening physical examination or laboratory evaluation, surgical alteration of scalp hair loss, use of drugs with androgenic or anti-androgenic properties in the past, or alopecia as result of other causes. The women did not alter their hairstyle or dye their hair during the study.
Lotion preparation and method ofapplication
Patients had to use this galenic lotion, composed of 2% minoxidil, 0.08% hydrocortisone butyrate, 0.05% 17a-estradiol, 16% ciclosilicone pentamer, 96°alcohol.
The topical lotion was applied 2 ml/die once a day on the scalp in the evening, for 36 months and the patients were followed-up for three years, during which time they were subjected to clinical and videodermatoscopic examinations every six months.
Instrumental examination
Measurement of hair density and recession of frontal hairline was undertaken by assessment of standardized global photographs that captured hair density in the vertex and in the anterior regions. A description of the preparation of the patient for each photographic view is as follows: (i) vertex scalp: hair was combed away from the vertex-like spokes of a wheel; (ii) anterior scalp: hair was center-parted and combed away from the parting for assessment of parting width and ease of seeing the scalp. All the photos were registered, using a macro-photograph 20-70X (Trichoscan Dermoscope Fotofinder®), before the treatment (TO) and every 6 months(T6) for 3 years. Effectiveness of the treatment was evaluated with a score for each patient, comparing photographs taken at baseline and at T36, then the paired photographs were rated separately based on a 4-point scale: -1 (worsened with regression of the frontal hair line and or absence of periauricolar hair), +1 (stabilized), +2 (improved) and +3 (greatly improved); these photos were examined by the same three experts (two dermatologists experienced in assessment of changes in scalp hair growth and one junior dermatologist). Improvement was defined as any regrowth of hair; stabilization was defined as arrest of hairline recession; and worsening was defined as progression of hairline recession. Changes in erythema or scalp symptoms were considered separately from changes in hair loss. As FFA progressively leads to permanent hair loss, which does not completely seem to correlate with the visible signs and symptoms of inflammation, we conclude that progression of hair loss has the greater influence in an outcome measure for FFA.
Statistical analysis
In order to verify the efficacy of the treatment from a statistical point of view, we considered the distribution of this score; we verified whether the patients are, or not, equally distributed between its different values. We used the Chi-square statistic and its associated level of probability and, secondary, we verified the distance between the observed distribution against the theoretical one (in case of perfect independency this implies to have the same ratio of patients in each different value of the score).
Then we verified that the proportion of patients with a generic improvement at T36 (i.e. with a score of + I, +2 or +3) was statistically different from the proportion of patients who resulted worsened. In this case, we used a normal approximation test based on a Binomial that allowed also to obtain a 95% confidence interval for such proportion. Table I shows the distribution of patients for the scores observed at the end of the observational period (T36) ; only 12.5% resulted as having no improvement and a great percentage of patients resulted stabilized (37.5%).
RESULTS
However, the majority of patients resulted improved or greatly improved (Figs. 1-3) . It should be observed that the average score was 1.5 which implies a general efficacy of the treatment to overcome the stabilization of the pathology.
More in detail, the Chi-square value in the distribution of the scores is 5, with an associated p-value of 0.171; this could be interpreted as a slight difference between the observed scores and the theoretical ones; however, when we distinguished between the generic improvement and the worsened situations (i.e. when we aggregate the scores + 1, +2 and +3 and we compare them against the value -1) we observe a Chi-square of 22.5 with a significant p-value (less than 0.0001). Furthermore , the Binomial proportion test gave us a value of the Z statistic s of -4.74 with a significant p-value (either for one or two-sided tests the p-value is less than 0.000 I). The 95% confidence interval obtained with the Binomial Proportion is in the range [0.022 :0.227] ; this means that, in the worst case and consid ering a more general experimental situation, 23% of patients (almost 1 in 4) did not have an improvement by using the treatment. On the contrary, for almost 3 patients in 4 the treatment will lead, at least, to a stabilization of the pathology or, more likely, to an improvement in the hair growth. No side effects were observed.
DISCUSSION
FFA is an uncommon inflammatory hair loss disease, characterized by a mild skin atrophy and a ., .,
'l it .
i N I' ' ' ' total loss of the follicular openings, with recession of the frontal hair line. It affects vellus-like hair in the frontoparietal region which usuall y occurs symmetrically and bilaterally.
Several topical or systemic treatments are proposed in literature to control FFA. Currentl y, there are no clinical trials of treatment for FFA and treatments are generally those used in the management of LPP, mostly based on small trials and case series (2) . Thus, treatment options vary among clinicians (3) .
Etiopathogenesis remains still not completely understood. The most validate theory is that the disease is characterized by autoreactive lymphocytic destruction of the hair follicle , especially involving vellus and miniaturized hair, usually located in the front hair-line and in the androgenetic region. The role of hormones in the pathogenesis remains obscure . Onset may occur after menopause, either iatrogenic or natural. Basing on this pathogenetic background, we decided to revaluate the physiological role of minoxidil, hydrocortisone butyrate and 17a-estradiol, to treat FFA.
Minoxidil, as reported in literature , is a potent arteriolar vasodilator becau se of its capacities as a potassium channel opener localized on the smooth muscular cells of the peripheral artery. Both the antihypertensive and the follicular effects of minoxidil are connected with its active metabolic derivate , minoxidil sulphate (14) . Although minoxidil has vasodilator function, when used systemically for hypertension, its mechanism of action in hair loss involves a direct stimulatory effect on dermal papilla or follicular hair matrix cell, increasing m-RNA expres sion for VEGF, and inducing angiogenesis (15) . Recently, it was supposed that minoxidil might activate the prostaglandine-endoperossidosynthetase enzyme type 1 which stimulates hair growth (16, 17) . Minoxidil appears to act by altering the hair cycle, through a combination of two effects, either shortening the telogen or prolonging the anagen phases (11). Moreover, this drug, inhibiting the enzyme Iysyl hydroxylase activity in human skin fibroblast cultures , leads to synthesi s of a collagen poor in hydroxylysine (18) , developing antifibrotic activity (17) . Therefore, this drug is useful in preventing the atrophy that can be observed in this disorder. Fig. 1. A, B, C, D) Clinical and videodermatoscopicfeatures at TO; (E, F, G, H) clinical and videodermatoscopicfeatures at T36. Fig. 2. A, B) Clinicalfeatures at TO and after 36 months. Hydrocortisone butyrate aims to block the mild inflammatory process, induced by lymphocytic perinfundibular and peristhmus infiltrate (12) (13) (14) (15) (16) (17) (18) (19) . This drug is a II class steroid that stabilizes the cellular membranes that activate and maintain microinflammation. Finally, 17a-estradiol is an oestrogen that has an effect on the measurable aromatase activity. In women, in frontal and occipital follicles there are high levels of cytochrome p-450 aromatase that has an important protective function on the frontal hair line. Indeed, oestrogens operate as potent hair growth modulators and as hair protective factors (20, 13, 21) . Under the influence of 17a-estradiol, an increased conversion of testosterone to 17~-estradio1 and androstendione to estrone is observed. Moreover, 17a-estradiol has a mild anti 5alpha-reductase activity. Aromatase is mainly localized within the root sheaths of the hair follicle in the frontal hairline and for this reason can be more easily accessible by a topical drug, when compared with the deep dermal papilla. Therefore, the application of 17a-estradiol at sufficient concentration is able to target hair follicles in vivo.
Indeed, 17a-estradiol topical use is functional to obtain thicker hair follicles in the frontal hairline which is the specific area involved in FFA, where the follicle is vellus-like and is in an aromatasedependent region (21, 22) .
Ciclosilicone pentamer and alcohol are useful to stabilize topical hair lotion, allowing an emollient action while inducing the components penetration. The use of a topical lotion based on minoxidil, hydrocortisone butyrate, 17a-estradiol, ciclosilicone pentamer, alcohol, 2 ml administered once a day on the scalp, leads to good results and is well tolerated (without any side effects).
Basing on the not still entirely understood etiopthatogenesis of FFA, we believe that the pathogenesis of this disorder involves many features: the inflammatory aspect and the hormonal aspect.
With this present study, we aim to highlight the effectiveness of a synergic therapy. Deeming FFA a hair-specific autoimmune disorder, characterized by a cell-mediated immune reaction against follicular keratinocytes, hydrocortisone acts primary on the mild inflammation. (2) . Minoxidil stimulates hair growth and prevents fibrosis. 17a-estradiol leads to hair growth and its use could be justified considering the frequent cases reported in the postmenopausal period, in which a relative reduction of oestrogen is observed. Satisfactory evidence-based medicine regimen for treating alopecias is available in literature only regarding alopecia areata and androgenetic alopecia. All the other recommendations for therapy of alopecia are still based on the literature review, expert opinion, personal experience, expected adverse effects, and some pragmatic considerations such as the cost and the patient's compliance. Cicatricial alopecias are one of the most difficult challenges for dermatologists, because these disorders are uncommon, the etiopathogenesis is not completely understood and the best therapy approach is not completely known. Therefore a universally-accepted form ofFFAmonotherapy does not exist. A drawback to our study is obviously the absence of a proper control, but two elements need to be considered: the first one is that FFA is a not common hair disorder, mainly because many cases ofFFA are not recognized by the dermatologist, and the diagnosis requires expert specialists; the second one is that untreated FFA leads to progressive hair loss and to fibrosis. Where fibrosis arises, new hair growth cannot appear, with reasonable aesthetical implications, especially in women. This aspect highly affects everyday life.
Considering the pathogenesis of the disease, we aim to reduce the onset of new vellus hairs, that could be attacked by inflammation, with progression of the disease and fibrosis. This lotion could be deemed as a valid approach in treating FFA, as it resulted as being able to stabilize mild inflammation, fibrosis and therefore hair loss, without having any side effects, common in systemic therapies, using the synergic actions of the different drugs. In view of the therapeutic capacity related to the strategic composition of the lotion with 17a-estradiol and hydrocortisone butyrate, the daily administration of the drug leads to an improvement in both the morphological and functional senses of the hair follicle while reducing the lymphocytic aggression. Additionally, minoxidil increases the follicle metabolic activity, preventing, and at the same time, improving sclerosis and fibrosis of the scalp. In this way, it can be assumed that the hair follicle becomes more resistant to lymphocytic aggression. Furthermore, the immunological potentiality of this molecule (14) , as demonstrated in literature, leads to the hypothesis that a general improvement in hair follicle would be unlikely to be attacked by the lymphocytes.
